一种双功能抑制剂CYT-1协同抑制热,以改善糖尿病脑病变的认知功能障碍
Youzhen Ma1, Maofang Zhao2, Chaoyi Zhang2
1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Department of Biophysics, School of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
International immunopharmacology
|June 29, 2025
概括
一种新的化合物,CYT-1,通过抑制NLRP3炎症酶和NF-κB通路,有效治疗糖尿病脑病变. 这种双重作用减少了神经元灭,并改善了小鼠的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 糖尿病脑病变 (DE) 是一种导致认知障碍的糖尿病并发症.
- 神经元热,一种编程细胞死亡的形式,是DE的关键机制.
- 现有的治疗方法针对NLRP3炎症体或NF-κB通路.
研究的目的:
- 设计一种双功能化合物,CYT-1,可以同时抑制NLRP3和NF-κB的激活.
- 为了研究CYT-1在抑制DE治疗中神经元灭的协同作用.
- 探索CYT-1作为糖尿病脑病变的新疗法策略.
主要方法:
- 在体外评估CYT-1对热致死途径蛋白和炎症因子的影响.
- 在DE小鼠中对CYT-1对H2S水平,热灭菌标志物和海马神经元计数的影响进行了体内评估.
- 采用西式涂抹和尼斯尔染色用于分子和组织学分析.
主要成果:
- 在体外,CYT-1显著降低了p-NF-κB,NLRP3,Caspase-1,GSDMD-N,IL-1β和IL-18的水平.
- 在DE小鼠中,CYT-1增加了血清和海马体H2S度.
- 在体内,CYT-1降低了热蛋白和增加了海马神经元数量.
结论:
- 通过同时抑制NF-κB和NLRP3炎症酶,CYT-1协同抑制神经元灭.
- CYT-1证明了糖尿病脑病变的治疗潜力.
- 这种双功能方法为DE药物开发和临床治疗提供了一个新的策略.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213
Dipeptidyl Peptidase 4 Inhibitors
270
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
270
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389


